Logo image of OYST

OYSTER POINT PHARMA INC (OYST) Stock Overview

NASDAQ:OYST - US69242L1061 - Common Stock

11.17 USD
+0.02 (+0.18%)
Last: 12/30/2022, 8:00:02 PM
11.17 USD
0 (0%)
After Hours: 12/30/2022, 8:00:02 PM

OYST Key Statistics, Chart & Performance

Key Statistics
52 Week High18.3
52 Week Low3.46
Market Cap299.85M
Shares26.84M
Float12.56M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-6.65
PEN/A
Fwd PEN/A
Earnings (Next)02-22 2023-02-22
IPO10-31 2019-10-31
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


OYST short term performance overview.The bars show the price performance of OYST in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

OYST long term performance overview.The bars show the price performance of OYST in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of OYST is 11.17 USD. In the past month the price decreased by -0.27%. In the past year, price decreased by -38.83%.

OYSTER POINT PHARMA INC / OYST Daily stock chart

OYST Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.00B
AMGN AMGEN INC 13.47 158.13B
GILD GILEAD SCIENCES INC 14.83 142.77B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 62.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.56B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 5.78 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.7 20.42B

About OYST

Company Profile

OYST logo image Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company is headquartered in Princeton, New Jersey and currently employs 303 full-time employees. The company went IPO on 2019-10-31. The firm is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The firm's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. The company is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Company Info

OYSTER POINT PHARMA INC

202 Carnegie Center, Suite 106

Princeton NEW JERSEY 08540 US

CEO: Jeffrey Nau

Employees: 303

OYST Company Website

Phone: 16093829032.0

OYSTER POINT PHARMA INC / OYST FAQ

What is the stock price of OYSTER POINT PHARMA INC today?

The current stock price of OYST is 11.17 USD. The price increased by 0.18% in the last trading session.


What is the ticker symbol for OYSTER POINT PHARMA INC stock?

The exchange symbol of OYSTER POINT PHARMA INC is OYST and it is listed on the Nasdaq exchange.


On which exchange is OYST stock listed?

OYST stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OYSTER POINT PHARMA INC stock?

10 analysts have analysed OYST and the average price target is 28.05 USD. This implies a price increase of 151.12% is expected in the next year compared to the current price of 11.17. Check the OYSTER POINT PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OYSTER POINT PHARMA INC worth?

OYSTER POINT PHARMA INC (OYST) has a market capitalization of 299.85M USD. This makes OYST a Micro Cap stock.


How many employees does OYSTER POINT PHARMA INC have?

OYSTER POINT PHARMA INC (OYST) currently has 303 employees.


What are the support and resistance levels for OYSTER POINT PHARMA INC (OYST) stock?

OYSTER POINT PHARMA INC (OYST) has a support level at 11.13 and a resistance level at 11.2. Check the full technical report for a detailed analysis of OYST support and resistance levels.


Is OYSTER POINT PHARMA INC (OYST) expected to grow?

The Revenue of OYSTER POINT PHARMA INC (OYST) is expected to grow by 55.43% in the next year. Check the estimates tab for more information on the OYST EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy OYSTER POINT PHARMA INC (OYST) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OYSTER POINT PHARMA INC (OYST) stock pay dividends?

OYST does not pay a dividend.


When does OYSTER POINT PHARMA INC (OYST) report earnings?

OYSTER POINT PHARMA INC (OYST) will report earnings on 2023-02-22.


What is the Price/Earnings (PE) ratio of OYSTER POINT PHARMA INC (OYST)?

OYSTER POINT PHARMA INC (OYST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.65).


OYST Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to OYST. When comparing the yearly performance of all stocks, OYST is one of the better performing stocks in the market, outperforming 95.5% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

OYST Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to OYST. OYST may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OYST Financial Highlights

Over the last trailing twelve months OYST reported a non-GAAP Earnings per Share(EPS) of -6.65. The EPS decreased by -113.14% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-101.47%
Sales Q2Q%-68.84%
EPS 1Y (TTM)-113.14%
Revenue 1Y (TTM)9.15%

OYST Forecast & Estimates

10 analysts have analysed OYST and the average price target is 28.05 USD. This implies a price increase of 151.12% is expected in the next year compared to the current price of 11.17.

For the next year, analysts expect an EPS growth of -66.47% and a revenue growth 55.43% for OYST


Analysts
Analysts78
Price Target28.05 (151.12%)
EPS Next Y-66.47%
Revenue Next Year55.43%

OYST Ownership

Ownership
Inst Owners0%
Ins Owners31.31%
Short Float %N/A
Short RatioN/A